Loading...

Newron Pharmaceuticals S.p.A.

0QOI.L•LSE
Healthcare
Medical - Pharmaceuticals
£7.14
£0.23(3.33%)

Newron Pharmaceuticals S.p.A. (0QOI.L) Stock Overview

Explore Newron Pharmaceuticals S.p.A.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 64.9/100

Key Financials

Market Cap138.7M
P/E Ratio-7.40
EPS (TTM)$-0.85
ROE1.28%
Fundamental Analysis

AI Price Forecasts

1 Week$7.17
1 Month$7.96
3 Months$7.22
1 Year Target$10.67

0QOI.L Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Newron Pharmaceuticals S.p.A. (0QOI.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 45.01, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $10.67.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -7.40 and a market capitalization of 138.7M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

45.01RSI (14)
-0.14MACD
15.96ADX
Stats data is not available for 0QOI.LStats details for 0QOI.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 0QOI.LAnalyst Recommendations details for 0QOI.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.

CEO

Stefan Weber

Employees

22

Headquarters

Via Antonio Meucci 3, Bresso, MI

Founded

2014

Frequently Asked Questions

;